Portfolio overlap

PBE / PBPH

Overlap	Shared positions
17.62%	13

Invesco Biotechnology & Genome ETF

Report dates 07/31/2026 | 100.05% NAV

Overlap / PBE 51.77%

Portfolio Building Block World Pharma and Biotech Index ETF

Report dates 07/31/2026 | 94.72% NAV

Overlap / PBPH 17.62%

Largest shared positions

Security	PBE	PBPH	Overlap
Amgen Inc.	5.22%	4.64%	4.64%
Gilead Sciences, Inc.	4.43%	3.77%	3.77%
Vertex Pharmaceuticals Inc.	4.99%	2.82%	2.82%

Weights are percentages of each fund's net assets. Shared weight is the sum of the smallest weight per matched common-stock class. Unmatched positions are excluded without renormalizing the weights.

History





2 matched portfolio dates from 04/30/2026 to 07/31/2026. Both filings use the same portfolio date. The minimum matched share of net assets is 94.72%. The filing dates are 52–60 days after the portfolio dates. This is filing lag. The archive does not establish an exact intraday release time.

Largest changes

04/30/2026 / 07/31/2026 +2.07 pp

Security	Overlap 04/30/2026	Overlap 07/31/2026	Change (pp)
Vertex Pharmaceuticals Inc.	0.00%	2.82%	+2.82
Gilead Sciences, Inc.	4.25%	3.77%	-0.48
Alnylam Pharmaceuticals, Inc.	1.06%	0.63%	-0.43
IONIS PHARMACEUTICALS INC	0.30%	0.00%	-0.30
Amgen Inc.	4.34%	4.64%	+0.30
All other shared classes			+0.16

Sources and methodology

Weights are percentages of each fund's net assets. Shared weight is the sum of the smallest weight per matched common-stock class. Unmatched positions are excluded without renormalizing the weights.

nport-common-equity-v1

Report dates	Weight (%)	Classes	PBE · SEC	PBPH · SEC
07/31/2026	17.62%	13	0001209466-26-001298	0002000324-26-004430
04/30/2026	15.55%	13	0001209466-26-000898	0002000324-26-002831